1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE DEEP BRAIN STIMULATION SYSTEMS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE EUROPE DEEP BRAIN STIMULATION SYSTEMS MARKET
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 MARKET GUIDE
2.2.4 COMPANY POSITIONING GRID
2.2.5 COMAPANY MARKET SHARE ANALYSIS
2.2.6 MULTIVARIATE MODELLING
2.2.7 TOP TO BOTTOM ANALYSIS
2.2.8 STANDARDS OF MEASUREMENT
2.2.9 VENDOR SHARE ANALYSIS
2.2.10 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.11 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 EUROPE DEEP BRAIN STIMULATION SYSTEMS MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 EPIDEOMOLOGY
6 PREMIUM INSIGHTS
6.1 PESTEL ANALYSIS
6.2 PORTER’S FIVE FORCES MODEL
7 INDUSTRY INSIGHTS
7.1 MICRO AND MACRO ECONOMIC FACTORS
7.2 PENETRATION AND GROWTH PROSPECT MAPPING
7.3 KEY PRICING STRATEGIES
7.4 INTERVIEWS WITH SPECIALIST
7.5 ANALYIS AND RECOMMENDATION
8 INTELLECTUAL PROPERTY (IP) PORTFOLIO
8.1 PATENT QUALITY AND STRENGTH
8.2 PATENT FAMILIES
8.3 LICENSING AND COLLABORATIONS
8.4 COMPETITIVE LANDSCAPE
8.5 IP STRATEGY AND MANAGEMENT
8.6 OTHER
9 COST ANALYSIS BREAKDOWN
10 TECHNONLOGY ROADMAP
11 INNOVATION TRACKER AND STRATEGIC ANALYSIS
11.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
11.1.1 JOINT VENTURES
11.1.2 MERGERS AND ACQUISITIONS
11.1.3 LICENSING AND PARTNERSHIP
11.1.4 TECHNOLOGY COLLABORATIONS
11.1.5 STRATEGIC DIVESTMENTS
11.2 NUMBER OF PRODUCTS IN DEVELOPMENT
11.3 STAGE OF DEVELOPMENT
11.4 TIMELINES AND MILESTONES
11.5 INNOVATION STRATEGIES AND METHODOLOGIES
11.6 RISK ASSESSMENT AND MITIGATION
11.7 FUTURE OUTLOOK
12 REGULATORY COMPLIANCE
12.1 REGULATORY AUTHORITIES
12.2 REGULATORY CLASSIFICATIONS
12.3 REGULATORY SUBMISSIONS
12.4 INTERNATIONAL HARMONIZATION
12.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
12.6 REGULATORY CHALLENGES AND STRATEGIES
13 REIMBURSEMENT FRAMEWORK
14 VALUE CHAIN ANALYSIS
15 HEALTHCARE ECONOMY
15.1 HEALTHCARE EXPENDITURE
15.2 CAPITAL EXPENDITURE
15.3 CAPEX TRENDS
15.4 CAPEX ALLOCATION
15.5 FUNDING SOURCES
15.6 INDUSTRY BENCHMARKS
15.7 GDP RATION IN OVERALL GDP
15.8 HEALTHCARE SYSTEM STRUCTURE
15.9 GOVERNMENT POLICIES
15.1 ECONOMIC DEVELOPMENT
16 EUROPE DEEP BRAIN STIMULATION SYSTEMS MARKET, BY PRODUCT TYPE
16.1 OVERVIEW
16.2 SINGLE-CHANNEL DEEP BRAIN STIMULATOR
16.2.1 MARKET VALUE (USD MILLION)
16.2.2 MARKET VOLUME (UNIT)
16.2.3 MARKET AVERAGE SELLING PRICE (USD)
16.3 DUAL-CHANNEL DEEP BRAIN STIMULATOR
16.3.1 MARKET VALUE (USD MILLION)
16.3.2 MARKET VOLUME (UNIT)
16.3.3 MARKET AVERAGE SELLING PRICE (USD
17 EUROPE DEEP BRAIN STIMULATION SYSTEMS MARKET, BY TYPE
17.1 OVERVIEW
17.2 RECHARGEABLE
17.2.1 MARKET VALUE (USD MILLION)
17.2.2 MARKET VOLUME (UNIT)
17.2.3 MARKET AVERAGE SELLING PRICE (USD)
17.3 NON-RECHARGEABLE
17.3.1 MARKET VALUE (USD MILLION)
17.3.2 MARKET VOLUME (UNIT)
17.3.3 MARKET AVERAGE SELLING PRICE (USD)
18 EUROPE DEEP BRAIN STIMULATION SYSTEMS MARKET, BY APPLICATION
18.1 OVERVIEW
18.2 NEUROLOGICAL DISORDERS
18.2.1 ALZHEIMER'S
18.2.1.1. SINGLE-CHANNEL DEEP BRAIN STIMULATOR
18.2.1.2. DUAL-CHANNEL DEEP BRAIN STIMULATOR
18.2.2 PARKINSONS
18.2.2.1. SINGLE-CHANNEL DEEP BRAIN STIMULATOR
18.2.3 DUAL-CHANNEL DEEP BRAIN STIMULATOR
18.2.4 EPILEPSY
18.2.4.1. SINGLE-CHANNEL DEEP BRAIN STIMULATOR
18.2.5 DUAL-CHANNEL DEEP BRAIN STIMULATOR
18.2.6 ESSENTIAL TREMOR
18.2.6.1. SINGLE-CHANNEL DEEP BRAIN STIMULATOR
18.2.7 DUAL-CHANNEL DEEP BRAIN STIMULATOR
18.2.8 TOURETTE’S SYNDROME
18.2.8.1. SINGLE-CHANNEL DEEP BRAIN STIMULATOR
18.2.9 DUAL-CHANNEL DEEP BRAIN STIMULATOR
18.2.10 OTHERS
18.3 CHRONIC PAIN
18.3.1 SINGLE-CHANNEL DEEP BRAIN STIMULATOR
18.3.2 DUAL-CHANNEL DEEP BRAIN STIMULATOR
18.4 DEPRESSION & OBSESSIVE COMPULSIVE DISORDER
18.4.1 SINGLE-CHANNEL DEEP BRAIN STIMULATOR
18.4.2 DUAL-CHANNEL DEEP BRAIN STIMULATOR
18.5 POST TRAUMATIC COMA
18.5.1 SINGLE-CHANNEL DEEP BRAIN STIMULATOR
18.5.2 DUAL-CHANNEL DEEP BRAIN STIMULATOR
18.6 DYSTONIA
18.6.1 SINGLE-CHANNEL DEEP BRAIN STIMULATOR
18.6.2 DUAL-CHANNEL DEEP BRAIN STIMULATOR
18.7 PAIN MANAGEMENT
18.7.1 SINGLE-CHANNEL DEEP BRAIN STIMULATOR
18.7.2 DUAL-CHANNEL DEEP BRAIN STIMULATOR
18.8 OTHERS
19 EUROPE DEEP BRAIN STIMULATION SYSTEMS MARKET, BY END USER
19.1 HOSPITALS
19.2 AMBULATORY SURGICAL CENTERS (ASC'S)
19.3 NEUROLOGICAL CLINIC
19.4 OTHERS
20 EUROPE DEEP BRAIN STIMULATION SYSTEMS MARKET, BY DISTRIBUTION CHANNEL
20.1 OVERVIEW
20.2 DIRECT TENDER
20.3 RETAIL SALES
20.4 OTHERS
21 EUROPE DEEP BRAIN STIMULATION SYSTEMS MARKET, BY GEOGRAPHY
EUROPE DEEP BRAIN STIMULATION SYSTEMS MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
21.1 EUROPE
21.1.1 GERMANY
21.1.2 FRANCE
21.1.3 U.K.
21.1.4 ITALY
21.1.5 SPAIN
21.1.6 RUSSIA
21.1.7 TURKEY
21.1.8 BELGIUM
21.1.9 NETHERLANDS
21.1.10 NORWAY
21.1.11 FINLAND
21.1.12 SWITZERLAND
21.1.13 DENMARK
21.1.14 SWEDEN
21.1.15 POLAND
21.1.16 REST OF EUROPE
21.2 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
22 EUROPE DEEP BRAIN STIMULATION SYSTEMS MARKET,COMPANY LANDSCAPE
22.1 COMPANY SHARE ANALYSIS: EUROPE
22.2 MERGERS & ACQUISITIONS
22.3 NEW PRODUCT DEVELOPMENT AND APPROVALS
22.4 EXPANSIONS
22.5 REGULATORY CHANGES
22.6 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
23 EUROPE DEEP BRAIN STIMULATION SYSTEMS MARKET, SWOT & DBMR ANALYSIS
24 EUROPE DEEP BRAIN STIMULATION SYSTEMS MARKET, COMPANY PROFILE
24.1 ABBOTT
24.1.1 COMPANY SNAPSHOT
24.1.2 REVENUE ANALYSIS
24.1.3 GEOGRAPHIC PRESENCE
24.1.4 PRODUCT PORTFOLIO
24.1.5 RECENT DEVELOPMENT
24.2 MEDTRONIC
24.2.1 COMPANY SNAPSHOT
24.2.2 REVENUE ANALYSIS
24.2.3 GEOGRAPHIC PRESENCE
24.2.4 PRODUCT PORTFOLIO
24.2.5 RECENT DEVELOPMENT
24.3 BOSTON SCIENTIFIC CORPORATION
24.3.1 COMPANY SNAPSHOT
24.3.2 REVENUE ANALYSIS
24.3.3 GEOGRAPHIC PRESENCE
24.3.4 PRODUCT PORTFOLIO
24.3.5 RECENT DEVELOPMENT
24.4 SCENERAY CO., LTD
24.4.1 COMPANY SNAPSHOT
24.4.2 REVENUE ANALYSIS
24.4.3 GEOGRAPHIC PRESENCE
24.4.4 PRODUCT PORTFOLIO
24.4.5 RECENT DEVELOPMENT
24.5 ALEVA NEUROTHERAPEUTICS
24.5.1 COMPANY SNAPSHOT
24.5.2 REVENUE ANALYSIS
24.5.3 GEOGRAPHIC PRESENCE
24.5.4 PRODUCT PORTFOLIO
24.5.5 RECENT DEVELOPMENT
24.6 BIOINDUCTION LTD
24.6.1 COMPANY SNAPSHOT
24.6.2 REVENUE ANALYSIS
24.6.3 GEOGRAPHIC PRESENCE
24.6.4 PRODUCT PORTFOLIO
24.6.5 RECENT DEVELOPMENT
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
25 CONCLUSION
26 QUESTIONNAIRE
27 RELATED REPORTS
28 ABOUT DATA BRIDGE MARKET RESEARCH